Genentech Polivy’s Benefit-Risk Profile In First-Line Lymphoma Under Scrutiny

 
• By Sue Sutter
  
First step
Genentech is seeking to make Polivy an option in the first-line setting. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers